Last updated on August 2017

Management of Acute Stroke Patients on Treatment with New Oral Anticoagulants: Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry”


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Stroke
  • Age: 18 Years
  • Gender: Male or Female

Inclusion Criteria

Patients are eligible to be included in the study if they meet the following criteria:
  1. Age 18 years or older
  2. Have been diagnosed with acute ischemic stroke and have been treated with dabigatran, rivaroxaban, apixaban, edoxaban within 7 days prior to admission, or
  3. Have been diagnosed with intracerebral hemorrhage and have been treated with warfarin or one of the new oral anticoagulants within 7 days prior to admission
  4. ARAMIS PRO follow-up study: Ability of patient or legally authorized representative to provide informed consent for longitudinal follow-up indicating they understand the purpose and the requirements of the study and are willing to participate.

Exclusion Criteria

  • Patients who were transferred from another hospital or discharged to other acute care facility will be excluded.

  • Recruitment Status: Open


    Brief Description Eligibility Contact Research Team


    Receive Emails About New Clinical Trials!

    Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.